In patients with diabetes mellitus, SGLT2 inhibitors increase glucosuria by blocking glucose reabsorption in the renal proximal tubule, and hence lower plasma glucose levels, independent of insulin stimulation [17]. Here, SLC5A2 is linked to diabetes mellitus.